Immuno-onocology is grabbing a large share of the headlines in
oncology drug development these days and generating significant buzz for
Big Pharma companies including Merck and Bristol-Myers Squibb (NYSE: BMY ) . While Pfizer (NYSE: PFE )
has not been seen as a leader in IO drug development, the company does
have antibodies in development targeting IO targets like 4-1BB, OX-40,
and PD-1. Now the company has added more shots on goal to its IO
platform, striking a collaboration agreement with French biotech Cellectis to develop chimeric antigen receptor T-cell therapies, an unproven but high-potential emerging therapeutic class.
Please follow this link for more:
Is Pfizer Putting the Car-T Before the Horse?
No comments:
Post a Comment